KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor

To measure the impact of donor selection for KIR genotype in allogeneic HCT for AML on cumulative incidence of relapse. This study will evaluate the incidence of relapse-free survival and overall survival, as well as endpoints not expected to be influenced by donor KIR selection including engraftment, GVHD and TRM. This study will determine the percentage of searches utilizing KIR genotyping to choose the best available KIR donor.

Study Number: 

NCG 191211

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail